Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANTAGE study of volixibat for cholestatic pruritus in primary biliary cholangitis
MOH_2022-02-01_010532Phase 2Not yet recruiting
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of volixibat in primary biliary cholangitis (PBC) (3 arms), sponsored by Mirum Pharmaceuticals, Inc. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
volixibat
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2022-02-01_010532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-01_010532.